Regencell Bioscience/$RGC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Regencell Bioscience
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
Ticker
$RGC
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Causeway Bay, Hong Kong
Employees
12
ISIN
KYG7487R1002
Website
RGC Metrics
BasicAdvanced
$10B
-
-$0.01
2.62
-
Price and volume
Market cap
$10B
Beta
2.62
52-week high
$83.60
52-week low
$0.08
Average daily volume
1.6M
Financial strength
Current ratio
41.916
Quick ratio
41.127
Long term debt to equity
0.316
Total debt to equity
1.043
Profitability
EBITDA (TTM)
-4.431
Management effectiveness
Return on assets (TTM)
-28.11%
Return on equity (TTM)
-43.18%
Valuation
Price to book
1,214.8
Price to tangible book (TTM)
1,214.8
Price to free cash flow (TTM)
-2,491.67
Free cash flow yield (TTM)
-0.04%
Free cash flow per share (TTM)
-0.81%
Growth
Earnings per share change (TTM)
-26.73%
3-year earnings per share growth (CAGR)
34.89%
Bulls say / Bears say
Regencell Bioscience's stock surged by 11.14% in pre-market trading on May 8, 2025, indicating positive investor sentiment possibly due to strategic partnerships or advancements in biotechnology. (AInvest)
The company's focus on traditional Chinese medicine for treating neurocognitive disorders positions it uniquely in a growing market segment, potentially leading to increased demand for its products. (GuruFocus)
Regencell's stock has experienced significant gains, with a notable increase of 5.97% recently, reflecting growing investor confidence in its business model and market potential. (GuruFocus)
The company reported zero revenue and a net loss of $4.3 million, leading to a negative earnings per share of -$0.33, which may raise concerns about its financial sustainability. (GuruFocus)
Regencell's stock price plummeted by 6.23% amid market volatility, indicating potential instability and investor apprehension. (AInvest)
The company's lack of operating revenue and ongoing net losses may deter investors seeking financially stable opportunities. (GuruFocus)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
RGC Financial Performance
Revenues and expenses
RGC News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Regencell Bioscience stock?
Regencell Bioscience (RGC) has a market cap of $10B as of June 27, 2025.
What is the P/E ratio for Regencell Bioscience stock?
The price to earnings (P/E) ratio for Regencell Bioscience (RGC) stock is 0 as of June 27, 2025.
Does Regencell Bioscience stock pay dividends?
No, Regencell Bioscience (RGC) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Regencell Bioscience dividend payment date?
Regencell Bioscience (RGC) stock does not pay dividends to its shareholders.
What is the beta indicator for Regencell Bioscience?
Regencell Bioscience (RGC) has a beta rating of 2.62. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.